Investigational drugs for endometriosis

Chlouber RO, Richard O Chlouber, David L. Olive, Olive DL, Elizabeth A. Pritts, Pritts EA
Expert opinion on investigational drugs · 2006 · vol. 15(4) , pp. 399–407 · doi:10.1517/13543784.15.4.399 · PMID:16548789 · W2157932333
review OA: closed CC0 ⤵ 8 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

New investigational drugs for endometriosis target various pathophysiological pathways to effectively treat lesions while potentially minimizing side effects and preserving fertility.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Endometriosis is an enigmatic disease found in as many as 30% of reproductive age women. The symptoms for women who suffer from this malady vary but may include subfertility or chronic pelvic pain. Because endometriosis lesions rely on estradiol for growth, most of the existing drug regimens work by creating hypoestrogenism. Unfortunately, this leads to untoward side effects and alterations in ovulation and, subsequently, fertility potential. Newer drugs are currently under investigation that either create hypoestrogenemia more efficaciously or do not alter ovulation but still affect the growth of endometriosis. They target some of the pathophysiological pathways that are only now being elucidated, and include gonadotropin-releasing hormone antagonists, aromatase inhibitors, selective progesterone receptor modulators, angiogenesis inhibitors, matrix metalloprotease inhibitors, estrogen receptor beta-agonists and immune modulators.

My notes (saved in your browser only)

Condition tags

endometriosischronic_pelvic_pain

MeSH descriptors

Drugs, Investigational Endometriosis Aromatase Inhibitors Aromatase Inhibitors Drugs, Investigational Endometriosis Endometriosis Female Hormone Antagonists Hormone Antagonists Humans

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (62)

Cited by (8)

SciLite annotations

chemicals 1
estradiol

Source provenance

europepmc
last seen: 2026-08-29T06:12:09.280863+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:15:23.967219+00:00
scilite
last seen: 2026-05-18T04:57:49.680383+00:00
unpaywall
last seen: 2026-08-29T06:28:44.313744+00:00
License: CC0 · commercial use OK